The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Anti-Inflammatory Activities of a Chinese Herbal Formula IBS-20 In Vitro and In Vivo.
Zhonghan Yang; Viktoriya Grinchuk; Siu Po Ip; Chun-Tao Che; Harry H S Fong; Lixing Lao; Justin C Wu; Joseph J Sung; Brian Berman; Terez Shea-Donohue; et al. (Profiled Authors: Lixing Lao; Terez Shea-Donohue; Aiping M Zhao; Brian M Berman)
Department of Medicine and Mucosal Biology Research Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Evidence-based complementary and alternative medicine : eCAM 2012;2012():491496.
Irritable bowel syndrome (IBS) is a functional bowel disorder and the etiology is not well understood. Currently there is no cure for IBS and no existing medication induces symptom relief in all patients. IBS-20 is a 20-herb Chinese medicinal formula that offers beneficial effects in patients with IBS; however, the underlying mechanisms are largely unknown. This study showed that IBS-20 potently inhibited LPS- or IFNΓ-stimulated expression of pro-inflammatory cytokines, as well as classically activated macrophage marker nitric oxide synthase 2. Similarly, IBS-20 or the component herb Coptis chinensis decreased LPS-stimulated pro-inflammatory cytokine secretion from JAWS II dendritic cells. IBS-20 or the component herbs also blocked or attenuated the IFNΓ-induced drop in transepithelial electric resistance, an index of permeability, in fully differentiated Caco-2 monolayer. Finally, the up-regulation of key inflammatory cytokines in inflamed colon from TNBS-treated mice was suppressed significantly by orally administrated IBS-20, including IFNΓ and IL-12p40. These data indicate that the anti-inflammatory activities of IBS-20 may contribute to the beneficial effects of the herbal extract in patients with IBS, providing a potential mechanism of action for IBS-20. In addition, IBS-20 may be a potential therapeutic agent against other Th1-dominant gut pathologies such as inflammatory bowel disease.
1 Originating Grant
1 June 2009 - 31 March 2014
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Yungwui Tjong; Siupo Ip; Lixing Lao; Harry H S Fong; Joseph J Y Sung; Brian Berman; Chuntao CheJournal of ethnopharmacology 2011;135(3):754-61.
Y-W Tjong; S-P Ip; L Lao; J Wu; H H S Fong; J J Y Sung; B Berman; C-T CheNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 2011;23(7):666-e278.
Siu-Po Ip; Ming Zhao; Yanfang Xian; Mengli Chen; Yuying Zong; Yung-Wui Tjong; Sam-Hip Tsai; Joseph J Y Sung; Alan Bensoussan; Brian Berman; et al.Chinese medicine 2010;5():8.
Appears in this Publication
Author of this Publication